Kay E. Davies
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kay E. Davies has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Anne E. Deconinck
2 shared publicationsAllyson C. Potter
1 shared publicationDavid Hilton-Jones
Muscular Dystrophy Group, Muscle and Nerve Centre, Radcliffe Infirmary , Oxford OX2 6HE, UK
1 shared publicationDerek J. Blake
Genetics Unit, Department of Biochemistry, University of Oxford , South Parks Road, Oxford OX1 3QU, UK
1 shared publication- Derek J. Blake
Genetics Laboratory, Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK OX1 3QU
1 shared publication Grethe S. Foss
Genetics Unit, Biochemistry Department, Oxford University, South Parks Road, Oxford, OX1 3QU, UK
1 shared publication
Latest Publications
- 1 May 1998
- Published by Springer Nature in Nature Genetics
- Vol. 19 (1) , 79-82
Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice
Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease usually resulting in death of patients by their early twenties. In contrast, mice lacking dystrophin (Dmd(mdx)), appear physically normal despite their underlying muscle pathology. Mice deficient for both dystrophin and the dystrophin-related protein, utrophin, (Dmd(mdx);Utrn-/- mice) die between 6 and 20 weeks of age suffering from severe muscle weakness with joint contractures, pronounced growth retardation and kyphosis, suggesting that dystrophin and utrophin play complementary roles. The exact cause of death in these mice was not determined. Here we show that expression of a truncated utrophin transgene solely within the skeletal muscle of these mutants prevents premature death and the development of any clinical phenotype. In the absence of full-length dystrophin and utrophin, the presence of truncated utrophin also decreases muscle fibre regeneration, relocalizes the dystrophin protein complex to the sarcolemma and re-establishes a normal expression pattern of developmental muscle proteins. These data suggest that Dmd(mdx);Utrn-/- mice succumb to a skeletal muscle defect and that their reduced lifespan is not due to cardiac or neurogenic components. The phenotypic rescue observed demonstrates that the Dmd(mdx);Utrn-/- mice are an ideal model for testing gene delivery protocols for the expression of utrophin or dystrophin in skeletal muscle. To determine the cause of death of the Dmd(mdx):Utrn-/- mice.
- 1 May 1998
- Published by Springer Nature in Nature Genetics
- Vol. 19 (1) , 79-82
Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice
Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease usually resulting in death of patients by their early twenties. In contrast, mice lacking dystrophin (Dmd(mdx)), appear physically normal despite their underlying muscle pathology. Mice deficient for both dystrophin and the dystrophin-related protein, utrophin, (Dmd(mdx);Utrn-/- mice) die between 6 and 20 weeks of age suffering from severe muscle weakness with joint contractures, pronounced growth retardation and kyphosis, suggesting that dystrophin and utrophin play complementary roles. The exact cause of death in these mice was not determined. Here we show that expression of a truncated utrophin transgene solely within the skeletal muscle of these mutants prevents premature death and the development of any clinical phenotype. In the absence of full-length dystrophin and utrophin, the presence of truncated utrophin also decreases muscle fibre regeneration, relocalizes the dystrophin protein complex to the sarcolemma and re-establishes a normal expression pattern of developmental muscle proteins. These data suggest that Dmd(mdx);Utrn-/- mice succumb to a skeletal muscle defect and that their reduced lifespan is not due to cardiac or neurogenic components. The phenotypic rescue observed demonstrates that the Dmd(mdx);Utrn-/- mice are an ideal model for testing gene delivery protocols for the expression of utrophin or dystrophin in skeletal muscle. To determine the cause of death of the Dmd(mdx):Utrn-/- mice.
- Open Access
- 1 March 1998
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 7 (3) , 441-448
Expression of the murine homologue of FMR2 in mouse brain and during development.
The expression of the FRAXE fragile site on the human X chromosome is associated with the expansion of a CCG repeat at the 5' end of the FMR2 gene. The repeat expansion results in transcriptional silencing of the gene and this event has been found to be associated with mild mental handicap in families. We have previously shown that the gene is particularly abundantly expressed in the hippocampus and amygdala by northern analysis. Here we demonstrate the expression pattern of the homologous gene in adult mouse brain and early mouse embryos. High levels of fmr2 mRNA were noted in the hippocampus, the piriform cortex, Purkinje cells and the cingulate gyrus. Expression of fmr2 occurs on, or before, day 7 in the embryo and reaches its highest levels at 10.5-11.5 days. A more detailed analysis shows that the fmr2 expression in the embryo at 11 days is more specific and evident to the roof of the hind brain and the lateral ventricle of the brain. The coding sequence of the mouse fmr2 gene shows very high conservation with 88% amino acid identity to the human FMR2 sequence.
- 1 March 1998
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 7 (3) , 441-448
Open AccessExpression of the murine homologue of FMR2 in mouse brain and during development.
The expression of the FRAXE fragile site on the human X chromosome is associated with the expansion of a CCG repeat at the 5' end of the FMR2 gene. The repeat expansion results in transcriptional silencing of the gene and this event has been found to be associated with mild mental handicap in families. We have previously shown that the gene is particularly abundantly expressed in the hippocampus and amygdala by northern analysis. Here we demonstrate the expression pattern of the homologous gene in adult mouse brain and early mouse embryos. High levels of fmr2 mRNA were noted in the hippocampus, the piriform cortex, Purkinje cells and the cingulate gyrus. Expression of fmr2 occurs on, or before, day 7 in the embryo and reaches its highest levels at 10.5-11.5 days. A more detailed analysis shows that the fmr2 expression in the embryo at 11 days is more specific and evident to the roof of the hind brain and the lateral ventricle of the brain. The coding sequence of the mouse fmr2 gene shows very high conservation with 88% amino acid identity to the human FMR2 sequence.
- 31 December 1997
- Published by Elsevier in Neuromuscular Disorders
- Vol. 7 (8) , 482-486
Challenges in Duchenne muscular dystrophy
- 31 December 1997
- Published by Elsevier in Neuromuscular Disorders
- Vol. 7 (8) , 482-486
Challenges in Duchenne muscular dystrophy
- Open Access
- 1 July 1997
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 6 (7) , 1185-1191
Dystrobrevin deficiency at the sarcolemma of patients with muscular dystrophy
Mutations in the genes encoding dystrophin or dystrophin-associated proteins are responsible for Duchenne muscular dystrophy or various forms of limb-girdle muscular dystrophies respectively. We have recently cloned the gene for the murine 87 kDa postsynaptic protein dystrobrevin, a dystrophin-associated protein. Anti-dystrobrevin antibodies stain the sarcolemma in normal skeletal muscle indicating that dystrobrevin co-localises with dystrophin and the dystrophin-associated protein complex. By contrast, dystrobrevin membrane staining is severely reduced in muscles of Duchenne muscular dystrophy patients, consistent with dystrobrevin being a dystrophin-associated protein. Interestingly, dystrobrevin staining at the sarcolemma is dramatically reduced in patients with limb-girdle muscular dystrophy arising from the loss of one or all of the sarcoglycan components. Normal dystrobrevin staining is observed in patients with other forms of limb-girdle muscular dystrophy where dystrophin and the rest of the dystrophin-associated protein complex are normally expressed and in other neuromuscular disorders. Our results show that dystrobrevin-deficiency is a generic feature of dystrophies linked to dystrophin and the dystrophin-associated proteins. This is the first indication that a cytoplasmic component of the dystrophin-associated protein complex may be involved in the pathogenesis of limb-girdle muscular dystrophy.
- 1 July 1997
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 6 (7) , 1185-1191
Open AccessDystrobrevin deficiency at the sarcolemma of patients with muscular dystrophy
Mutations in the genes encoding dystrophin or dystrophin-associated proteins are responsible for Duchenne muscular dystrophy or various forms of limb-girdle muscular dystrophies respectively. We have recently cloned the gene for the murine 87 kDa postsynaptic protein dystrobrevin, a dystrophin-associated protein. Anti-dystrobrevin antibodies stain the sarcolemma in normal skeletal muscle indicating that dystrobrevin co-localises with dystrophin and the dystrophin-associated protein complex. By contrast, dystrobrevin membrane staining is severely reduced in muscles of Duchenne muscular dystrophy patients, consistent with dystrobrevin being a dystrophin-associated protein. Interestingly, dystrobrevin staining at the sarcolemma is dramatically reduced in patients with limb-girdle muscular dystrophy arising from the loss of one or all of the sarcoglycan components. Normal dystrobrevin staining is observed in patients with other forms of limb-girdle muscular dystrophy where dystrophin and the rest of the dystrophin-associated protein complex are normally expressed and in other neuromuscular disorders. Our results show that dystrobrevin-deficiency is a generic feature of dystrophies linked to dystrophin and the dystrophin-associated proteins. This is the first indication that a cytoplasmic component of the dystrophin-associated protein complex may be involved in the pathogenesis of limb-girdle muscular dystrophy.
- 31 August 1996
- Published by Elsevier in Trends in Genetics
- Vol. 12 (8) , 294-298
The genetic basis of neuromuscular disorders
- 31 August 1996
- Published by Elsevier in Trends in Genetics
- Vol. 12 (8) , 294-298
The genetic basis of neuromuscular disorders